期刊文献+

去甲万古霉素治疗老年人下呼吸道耐甲氧西林葡萄球菌感染43例临床分析 被引量:7

Clinical evaluation of norvancomycin on lower respiratory tract infection with methicillin resistant Staphylococcus in elderly patients
暂未订购
导出
摘要 目的通过对盐酸去甲万古霉素在老年人下呼吸道耐甲氧西林葡萄球菌(MRS)感染疗效和安全性分析,为去甲万古霉素在老年人群中的临床合理应用提供依据。方法观察了43例使用去甲万古霉素治疗的老年患者,并与同期住院30例老年患者采用万古霉素治疗比较,观察其临床疗效,细菌清除率和药物不良反应。结果去甲万古霉素在老年患者中的治愈率为20%,有效率为79%,细菌清除率76.7%,不良反应发生率5.4%;在万古霉素治疗组中分别为23%、80%、80%和6.6%,两组相比无显著性差异(P>0.05)。结论盐酸去甲万古霉素对老年人下呼吸道感染疗效良好,耐受性良好,但对原有肾脏疾病与合并使用多种药物患者,去甲万古霉素应慎用。 Objective To evaluate the susceptibility, clinical efficacy and adverse effects of norvancomycin on lower respiratory tract infections caused by methicillin resistant Staplylococcus (MRS) in elderly patients. Methods Seventy-three elderly patients of MRS lower respiratory tract infections were randomly divided into two groups. Patients (n= 43) were administered with domestic norvancomycin in treatment group, 0.5g, iv gtt qSh. The control group (n= 30) were treated with US made vancomycin 0. 5g, iv gtt, qSh. Result In the treatment group, the cure rate was 20%, the effective rate 79%, the bacteria eradication rate 76.7%, and the adverse effect rate 5.4%. Accordingly, the four parameters of the control group were 23%, 80%, 80% and 6.6% respectively. There was no statistically significant difference between the two groups (P〉0. 05). Conclusion Norvaneomyein was effective, inexpensive and safe in treating MRS infection in elderly patient, but to those patients who had kidney disfunetion or had treated by many drugs, norvaneomyein should be used carefully.
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2007年第9期556-559,共4页 Chinese Journal of Antibiotics
关键词 MRS 盐酸去甲万古霉素 老年 下呼吸道感染 Methieillin-resistant Staphylococcus Elderly patient I.ower respiratory tract infections Norvancomycin
  • 相关文献

参考文献8

二级参考文献40

  • 1黄建荣,干梦九,钱汶,孙乃仙,孔海深,朱建国.凝固酶阴性葡萄球菌医院内感染与耐药性研究[J].浙江医科大学学报,1996,25(3):119-121. 被引量:3
  • 2Friedman MA, Shaughness B, Ritchin MS, et al. Physicians desk reference. 54th ed. Montraie: Medical Economics Company, 2000.1643-1644.
  • 3Gilbert DN, Moellering RC, Sande MA. Guide to antimicrobial therapy. 33th ed. Vermont:Antimicrobial Therapy,Inc.,2003. 62.
  • 4Nikolaeva Ⅳ, Anokhin VA, Bondarenko VM, et al. Drug resistance of Staphylococcusaureus strains, isolated from children with intestinal dysbacteriosis[J]. Zh MikrobiolEpidemiol Immunobiol, 2001,1:9-13.
  • 5Fiaccadori E, Maggiore U, Arisi A,et al. Outbreak of acute renal failure due tocefodizime-vancomycin association in a heart surgery unit[J]. Intensive Care Med, 2002,27:1819-1822.
  • 6Cunba BA. Vancomycin[J]. Med Clin North Am ,1995,79:817-831.
  • 7Climo M W, Patron R L, Archer G C. Combinations of vancomycin and β-1actams are synergistic against staphylococci with reduced susceptibilities to vancomyicn[J]. Antimicrob Agents Chemother, 1999,43:1747
  • 8Boyce J M, Medeiros A A. Clinical isolates of methicillin-resistant Staphylococcus aureus from the United States with subpopulations of cells with reduced susceptibility to vancomycin, abstr. LB-15[A] In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy[C]. Washington, D C: American Society for Microbiology, 1997:6
  • 9Centers for Disease Control and Prevention. Update: Staphylococcus aureus with reduced susceptibility to vancomycin United States[J].Morbid Mortal, 1997, 46:813
  • 10Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility[J]. J Antimicrob Chemother, 1997,40:135

共引文献105

同被引文献53

引证文献7

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部